Introduction
The immune reconstitution inflammatory syndrome or IRIS (elsewhere referred to as 'immune reconstitution disease', 'immune reconstitution syndrome' or 'immune restoration disease') is a widely recognised phenomenon that may complicate antiretroviral therapy (ART) 1, 2 . It results from rapid restoration of pathogen-specific immune responses to opportunistic infections (OI), causing either the deterioration of a treated OI or the new presentation of previously subclinical OI. IRIS typically occurs during the initial months of ART and is recognised to be associated with a wide spectrum of pathogens, most commonly mycobacteria, herpes viruses, and deep fungal infections such as cryptococcal meningitis [1] [2] [3] .
In recent years access to ART has increased rapidly in resource-limited settings, reaching a total of over 2 million people by December 2006 with an estimated 1 340 000 of these living in sub-Saharan Africa 4 . Since the burden of TB/HIV co-infection is very high in many low and middle income countries 5 , many patients enter ART programmes in these settings with a current diagnosis of TB or later develop TB following initiation of ART. For example, one South African study reported that 25% of patients were receiving TB treatment at ART initiation and a further 11% developed TB during the first year of ART 6 . A substantial number of patients in such programmes are therefore at risk of developing TB-IRIS and this condition has emerged as an important clinical challenge in resource-limited settings [7] [8] [9] [10] .
There is no diagnostic test for IRIS and diagnoses therefore rely heavily upon case definitions incorporating clinical and laboratory data. However, both clinical management and research on IRIS are hindered by the lack of consensus case definitions and definitions that are specific to particular opportunistic infections. An international meeting of around 100 researchers working in this field was convened in Kampala, Uganda, in November 2006 and the International Network for the Study of HIVassociated IRIS (INSHI) was formed ( Figure 1) . A specific aim of the meeting was to develop consensus case definitions for TB-IRIS that are appropriate for resource limited settings (where laboratory capacity is often limited) and that could be used by researchers working in different settings to permit comparability of results. We present these consensus case definitions in this paper.
Participants and consensus method
The need for a public health definition for TB-IRIS was first conceptualized at the World 12 , propose that a rise in peripheral blood CD4 cell count should not be a necessary condition for the diagnosis of TB-IRIS.
A further important modification to existing definitions is the inclusion of a time-frame of the first three months of ART. Onset of the clinical manifestations of TB-IRIS should occur within this time-frame for a diagnosis of TB-IRIS to be made since this is the period of most rapid immune recovery within which the vast majority of cases are concentrated 3, 19 .
Categories of TB-IRIS
TB-IRIS may present as one of two main syndromes: 1) a paradoxical reaction after the start of ART in patients receiving TB treatment (here termed 'paradoxical TB-IRIS') or
2) a new presentation of TB that is 'unmasked' in the weeks following initiation of ART that has an exaggerated inflammatory clinical presentation or is complicated by a paradoxical reaction (here termed 'unmasking TB-IRIS').
In the first of these two syndromes ('paradoxical TB-IRIS'), patients have a diagnosis of active TB established prior to initiation of ART and have typically been responding to antituberculosis treatment. Following initiation of ART, IRIS presents as the development of recurrent, new or worsening symptoms or signs of TB, such as return of cough, fever or lymph node enlargement, or recurrent, new or deteriorating radiological manifestations ( Figure 2 ). This typically occurs within the first few weeks and up to 3 months after ART is initiated, re-started, or changed due to treatment failure.
Reports of the incidence of 'paradoxical TB-IRIS' using a variety of existing case definitions range between 8% and 43% [8] [9] [10] [19] [20] [21] [22] [23] [24] [25] [26] ( Table 2 ). 'Paradoxical TB-IRIS' has been associated with large expansions of purified protein derivative (PPD)-specific Tcells in peripheral blood as well as increased pro-inflammatory cytokine levels 27 . Risk factors for TB-IRIS are shown in Table 2 and include more advanced HIV disease with lower CD4 cell count, disseminated and extrapulmonary TB, a shorter delay between the start of TB treatment and initiation of ART and a more vigorous immunological and virological response to ART. Most cases of 'paradoxical TB-IRIS' are self-limiting. The median duration of symptoms reported in the literature is 2 months 23, 25 , but the duration is very variable ranging from mild cases where symptoms resolve after a few days to isolated prolonged cases that have still been symptomatic after more than a year ( 23 and Figure 2 ). Mortality due to TB-IRIS has infrequently been reported in the literature 3, 9, 10, 25 , but morbidity and the need for hospitalisation and therapeutic procedures may be substantial 25 . In resource limited settings where diagnostic and treatment options are restricted, the mortality and morbidity attributable to 'paradoxical TB-IRIS' may be greater. Neurological TB-IRIS in particular may be associated with poor outcome.
TB paradoxical reactions, such as enlargement of lymph nodes or cerebral tuberculomas, also occur in HIV-uninfected individuals and HIV-infected individuals who are receiving appropriate TB treatment but who are not receiving ART [28] [29] [30] .
However, the frequency of paradoxical reactions is much greater with ART 21, 24 . In one study, paradoxical reactions on TB treatment occurred in 2% of HIV seronegative patients, 7% of HIV-infected patients not on ART and 36% of HIV-infected patients on TB treatment and ART 21 . The timing of the paradoxical reaction in this latter group was more closely related to the initiation of ART than TB treatment. Thus, the greatly increased frequency of paradoxical reactions in patients receiving ART suggests that ART-related immunological changes play an important role in their aetiology. In addition, our clinical experience is that 'paradoxical TB-IRIS' is more severe and more frequently a multisystem condition than paradoxical reactions in patients not receiving
ART.
There is less clarity surrounding the second major category of TB-IRIS ('unmasking TB-IRIS') than the first. High rates of TB have been described during ART, especially in the initial months of treatment in ART programmes in resource-limited settings 6, 31-34 .
The mechanisms underlying presentations of TB after initiating ART are likely to be Paradoxical reactions in patients started on TB treatment while on ART are also described 25, 38 and one study reported that paradoxical reactions are more frequent in patients who are diagnosed with TB in the first 3 months of ART than patients who start ART after TB treatment (62 versus 30%, p = 0.05) 38 . This suggests that ART-related immunological changes play a role in the development of paradoxical reactions in this group of patients.
Few cases of 'unmasking TB-IRIS' have been described in the literature to date [38] [39] [40] [41] .
In the absence of a diagnostic test, it is currently difficult to differentiate the varied mechanisms underlying the majority of cases of TB that present during early ART, especially in resource-limited settings where rates of TB are extremely high. We therefore propose that, as elsewhere 35 , the term 'ART-associated TB' be used to refer to all patients who present with active TB while receiving ART (Figure 4) . We also suggest a provisional case definition for 'unmasking TB-IRIS' and clinical scenarios where the diagnosis may be considered.
Further research into the clinical characteristics and immunological mechanisms underlying cases of 'ART-associated TB' may permit a more refined case definition for 'unmasking TB-IRIS' to be derived in the future. However, given the heterogeneity in the natural history and clinical manifestations of TB it is unlikely that a clinical case definition that robustly separates patients with 'unmasking TB-IRIS' from others with 'ART-associated TB' will be derived 35 .
Case Definitions
With the rationale described above, we have developed case definitions for 'paradoxical TB-IRIS', 'ART-associated TB' and 'unmasking TB-IRIS'. These case definitions have been designed for use in resource-constrained settings and are consensus case definitions that need validation in clinical practice.
Case Definition for 'paradoxical TB-IRIS' (summarised in Table 3)
There are three components (A, B and C) to this case definition.
A) Antecedant requirements
Both of the two following requirements must be met:
1) Diagnosis of TB:
The TB diagnosis was made before starting ART and this should fulfil World Health Organization (WHO) criteria for diagnosis of smear positive pulmonary TB (PTB), smear negative PTB or extrapulmonary TB 42 .
2) Initial response to TB treatment:
The patient's condition should have stabilised or improved on appropriate TB treatment prior to ART initiation e.g. cessation of night sweats, fevers, cough, weight loss. (Note: this does not apply to patients starting ART within 2 weeks of starting TB treatment as insufficient time may have elapsed for a clinical response to be observed).
B) Clinical Criteria
The onset of TB-IRIS manifestations should be within three months of ART initiation, re-initiation, or regimen change due to treatment failure. In these probable cases, should resolution of clinical or radiological findings of the suspected IRIS episode occur without a change in TB treatment or ART having been made they could then be reclassified as 'paradoxical TB-IRIS' cases.
Case definition for 'ART-associated TB'
We propose that 'ART-associated TB' (all cases of TB that are diagnosed during ART)
should be defined as follows.
1) Patient is not receiving treatment for TB when ART is initiated.
2) Active TB is diagnosed after initiation of ART.
3) The diagnosis of TB should fulfil WHO criteria for smear positive PTB, smear negative PTB or extrapulmonary TB 42 .
Case definition for 'unmasking TB-IRIS'
A sub-set of 'ART-associated TB' cases may be due to TB-IRIS. There are few reports in the literature upon which to base a case definition for this sub-set. Nonetheless we considered it necessary to propose a provisional case definition for this entity to assist researchers in collecting clinical and immunological data in order that a more refined case definition could be developed in the future. We propose that the following features may Data for this paper were obtained by searching Medline without time restrictions. Search terms included "immune reconstitution", "immune restoration", "immune recovery", "IRIS", "antiretroviral" and "tuberculosis" and "paradoxical reaction". Only English language papers were reviewed. In addition, unpublished data and TB-IRIS case definitions presented by researchers at the meeting were used. 2 In this study, 8 cases of the 9 were associated with TB, the other was associated with Mycobacterium avium complex (MAC).
Data shown are for all 9. 2) The patient's condition should have stabilised or improved on appropriate TB treatment prior to ART initiation (unless ART was started within 2 weeks of TB treatment).
B) Clinical criteria should be fulfilled
The onset of manifestations is within 3 months of ART initiation, re-initiation, or regimen change due to treatment failure. This was an unusually prolonged course for 'paradoxical TB-IRIS' given that the median duration of symptoms is reported to be 2 months. 
